Common cholesterol drug tested as potential lifeline for rare liver disease
Disease control
Ongoing
This large, late-stage study is testing whether a common cholesterol-lowering drug, simvastatin, can improve the long-term outlook for people with primary sclerosing cholangitis (PSC), a rare liver disease. About 570 adults with PSC will take either simvastatin or a placebo pill …
Phase: PHASE3 • Sponsor: Annika Bergquist • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC